Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 6, 2014, Pages 611-615

  Iacovelli, Roberto ^a   Palazzo, Antonella ^a   Trenta, Patrizia ^a   Mezi, Silvia ^a   Pellegrino, Denise ^a   Naso, Giuseppe ^a   Cortesi, Enrico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Axitinib; Everolimus; Renal cell carcinoma; Second line; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; ENZYME INHIBITION; HUMAN; KIDNEY METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; SECONDARY; TREATMENT FAILURE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; KIDNEY NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84916931755     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31827de888     Document Type: Review

References (25)

1. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
2. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794-5799.
3. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-3590.
4. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729-734.
5. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122-127.
6. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
7. Bojanapally PR, Graham S, Rustine AL, et al. Temsirolimus for advanced renal cell carcinoma: compassionate versus commercial use. J Clin Oncol. 2008;26(suppl): No 15S, [abstract 16139].
8. Schmidinger M, Vogel UM, Lamm W, et al. Temsirolimus in heavily pre-treated patients with metastatic renal cell carcinoma: preliminary results from the Austrian Compassionate Use Program. J Clin Oncol. 2008;26(suppl): [abstract 16125].
9. Mackenzie MJ, Rini BI, Elson P, et al. Temsirolimus in VEGFrefractory metastatic renal cell carcinoma. Ann Oncol. 2011;22: 145-148.
10. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265.
11. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
12. Porta C, Procopio G, Cartenì G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011;108:E250-E257.
13. Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009; 115:61-67.
14. Di Lorenzo G, Cartenì G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009;27:4469-4474.
15. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol. 2008;26(suppl): [abstract 5123].
16. Morabito A, De Maio E, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11:753-764.
17. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4462-4468.
18. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-1939.
19. Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16:122-131.
20. Rini BI, Flaherty K. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol. 2008;26:543-549.
21. Su X, Ranpura V, Wu S. Risk of primary progressive disease with tyrosine kinase inhibitors sorafenib and sunitinib in patients with renal cell carcinoma: a meta-analysis. J Clin Oncol. 2010;28(suppl):15s, [abstract 4616].
22. Heng DY, MacKenzie MJ, Vaishampayan UN, et al. Primary anti- VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy. J Clin Oncol. 2001;29(suppl 7): [abstract 305].
23. Albiges L, Iacovelli R, Porta C, et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib: is there any active treatment? Eur J Cancer. 2011;47: S522-S523.
24. Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer. 2012;10: 77-83.
25. Elaidi RT, Beuselinck B, Maj-HES A, et al. What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study. J Clin Oncol. 2012;30(suppl 5): [abstract 375].